Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report
暂无分享,去创建一个
Thomas Jaki | Christopher Brightling | Katie Jeffery | Timothy Felton | Andrew Ustianowski | Alan Montgomery | Jonathan R Emberson | David Chadwick | M. Landray | P. Horby | W. Lim | C. Brightling | C. Fegan | J. Emberson | J. Baillie | T. Jaki | A. Montgomery | K. Rowan | S. Faust | A. Ustianowski | N. Staplin | L. Chappell | K. Jeffery | E. Juszczak | M. Mafham | R. Haynes | B. Prudon | D. Chadwick | Louise Linsell | Peter Horby | Christopher Fegan | Edmund Juszczak | J. Bell | L. Linsell | E. Elmahi | C. Green | T. Felton | K. Rege | Saul N Faust | Lucy C Chappell | J Kenneth Baillie | Kathryn Rowan | Martin J Landray | Wei Shen Lim | Benjamin Prudon | Richard Haynes | Marion Mafham | Jennifer L Bell | Natalie Staplin | Einas Elmahi | Christopher Green | Kanchan Rege | A. Ustianowski | K. Jeffery | W. Lim | Peter W. Horby | Christopher A Green | J. K. Baillie | C. Brightling | E. Juszczak | J. R. Emberson | J. L. Bell | L. Linsell | N. Staplin | T. Felton | D. Chadwick | Christopher Fegan | L. Chappell | Saul N. Faust | T. Jaki | A. Montgomery | K. Rowan | R. Haynes | Peter W Horby | P. Horby | J. Emberson | C. Fegan | J. Baillie | S. Faust
[1] P. Vollmar,et al. Virological assessment of hospitalized patients with COVID-2019 , 2020, Nature.
[2] Yi Guan,et al. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia , 2006, Nature Medicine.
[3] Yan Zhao,et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. , 2020, JAMA.
[4] Louise Bowman,et al. The Magic of Randomization versus the Myth of Real-World Evidence. , 2020, The New England journal of medicine.
[5] W. Lim,et al. Viral shedding patterns of coronavirus in patients with probable severe acute respiratory syndrome , 2004, The Lancet.
[6] J. Sung,et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome , 2004, Clinical and experimental immunology.
[7] S. Zhang,et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series , 2020, BMJ.
[8] J. Xiang,et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study , 2020, The Lancet.
[9] V. Wong,et al. Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients , 2004, Journal of Clinical Virology.
[10] J. Baillie,et al. Influenza--time to target the host? , 2013, The New England journal of medicine.
[11] Rajaa Al-Raddadi,et al. Corticosteroid Therapy for Critically Ill Patients with Middle East Respiratory Syndrome , 2017, American journal of respiratory and critical care medicine.
[12] Andrea Gianatti,et al. Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study , 2020, The Lancet Infectious Diseases.
[13] J. Sung,et al. Viral Loads and Duration of Viral Shedding in Adult Patients Hospitalized with Influenza , 2009, The Journal of infectious diseases.
[14] C. Whittaker,et al. Estimates of the severity of coronavirus disease 2019: a model-based analysis , 2020, The Lancet Infectious Diseases.
[15] Sarah Parish,et al. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2.ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. , 1988, Journal of the American College of Cardiology.
[16] J. Riancho,et al. GLUCOCOVID: A controlled trial of methylprednisolone in adults hospitalized with COVID-19 pneumonia , 2020, medRxiv.
[17] G. Gao,et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019 , 2020, The New England journal of medicine.
[18] Xianbo Wu,et al. Viral dynamics in asymptomatic patients with COVID-19 , 2020, International Journal of Infectious Diseases.
[19] J. Baillie,et al. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury , 2020, The Lancet.
[20] Y. Hu,et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.
[21] Carl H. June,et al. Cytokine release syndrome in severe COVID-19 , 2020, Science.
[22] W. Tu,et al. Clinical Features and Short-term Outcomes of 102 Patients with Corona Virus Disease 2019 in Wuhan, China , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[23] Lee-Jen Wei,et al. Remdesivir for the Treatment of Covid-19 - Preliminary Report. , 2020, The New England journal of medicine.
[24] W. Lim,et al. Corticosteroids as Adjunctive Therapy in the Treatment of Influenza: An Updated Cochrane Systematic Review and Meta-analysis. , 2019, Critical care medicine.
[25] L. Bolognese,et al. RANDOMISED TRIAL OF INTRAVENOUS STREPTOKINASE, ORAL ASPIRIN, BOTH, OR NEITHER AMONG 17 187 CASES OF SUSPECTED ACUTE MYOCARDIAL INFARCTION: ISIS-2 , 1988, The Lancet.
[26] Yiu Chung Lau,et al. Temporal dynamics in viral shedding and transmissibility of COVID-19 , 2020, Nature Medicine.
[27] M. Zhou,et al. [Expert consensus on the use of corticosteroid in patients with 2019-nCoV pneumonia]. , 2020, Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases.
[28] P. Horby,et al. Scope, quality, and inclusivity of clinical guidelines produced early in the covid-19 pandemic: rapid review , 2020, BMJ.
[29] Y. Hu,et al. On the use of corticosteroids for 2019-nCoV pneumonia , 2020, The Lancet.
[30] R Peto,et al. Why do we need some large, simple randomized trials? , 1984, Statistics in medicine.
[31] Qiurong Ruan,et al. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China , 2020, Intensive Care Medicine.
[32] P. Horby,et al. Modernising epidemic science: enabling patient-centred research during epidemics , 2016, BMC Medicine.
[33] G. Guyatt,et al. Corticosteroid Therapy for Patients Hospitalized With Community-Acquired Pneumonia , 2015, Annals of Internal Medicine.
[34] J. González-Martín,et al. Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial. , 2020, The Lancet. Respiratory medicine.
[35] P. Horby,et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study , 2020, BMJ.
[36] Paul Garner,et al. SARS: Systematic Review of Treatment Effects , 2006, PLoS medicine.
[37] Medicines And Healthcare Products Regulatory Agency , 2020, Definitions.
[38] O. Tsang,et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study , 2020, The Lancet Infectious Diseases.
[39] Ting Yu,et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study , 2020, The Lancet.
[40] W. Lim,et al. Dexamethasone in Hospitalized Patients with Covid-19 , 2021 .